Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis.
Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis.
复制标题
DOI：
10.3748/wjg.v20.i4.1095
复制
发表时间：
2014-01
影响因子：
4.3
通讯作者：
Zheng-Xu Wang;Jun-Xia Cao;Zhi-Ping Liu;Yu-Xin Cui;Chun-Yun Li;Duo Li;Xiao-yan Zhang;Jin-long Liu;Jun-Li Li-Jun-Li-Li-2157344434
中科院分区：
文献类型：
--
作者：
Zheng-Xu Wang;Jun-Xia Cao;Zhi-Ping Liu;Yu-Xin Cui;Chun-Yun Li;Duo Li;Xiao-yan Zhang;Jin-long Liu;Jun-Li Li-Jun-Li-Li-2157344434
目的探讨自体树突状细胞（DC）细胞因子诱导杀伤（CIK）细胞疗法是否能够提高结肠癌化疗的疗效。方法 我们对 MEDLINE、Cochrane 对照试验中心注册库、EMBASE、万方数据库、中国科技期刊数据库和中国期刊网等来源的已发表论文进行了系统回顾。已发布的数据由两位作者使用预定义的数据库模板独立提取。还评估了单篇论文的数据质量。比较化疗与化疗联合DC-CIK免疫治疗的效果。使用随机或固定效应模型的数据进行汇总分析。结果 7 项试验符合我们的纳入标准 (n = 533)。总体分析显示显着的生存获益[一年总生存期（OS），P < 0.0001；两年 OS，P = 0.009；三年 OS，P = 0.002] 支持 DC-CIK 免疫治疗联合化疗。 DC-CIK免疫治疗与化疗联合后，无病生存率（DFS）得到改善（一年DFS，P < 0.0001；两年DFS，P = 0.002；三年DFS，P = 0.02）。在接受 DC-CIK 治疗的患者中还观察到总体缓解率有所提高 (P = 0.009)。此外，外周血T淋巴细胞亚群分析表明，DC-CIK联合化疗组CD4+ T细胞数量显着增加（P < 0.05）。结论 DC-CIK免疫治疗联合化疗在延长患者生存时间、增强免疫反应方面具有优越性。
AIM To investigate whether autologous dendritic cell (DC)-cytokine-induced killer (CIK) cell therapy is able to improve the therapeutic efficacy of chemotherapy in colon cancer. METHODS We conducted a systematic review of published papers from the sources of MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, the Wanfang Database, the China Science and Technology Periodical Database and China Journal Net. Published data were extracted independently by two authors using predefined database templates. The quality of the data from individual papers was also assessed. The effects of chemotherapy were compared with those of chemotherapy in combination with DC-CIK immunotherapy. The pooled analysis was performed using the data from random or fixed-effect models. RESULTS Seven trials matched our inclusion criteria (n = 533). The overall analysis showed significant survival benefit [one-year overall survival (OS), P < 0.0001; two-year OS, P = 0.009; three-year OS, P = 0.002] in favor of DC-CIK immunotherapy combined with chemotherapy. Disease-free survival (DFS) rate was improved after the combination of DC-CIK immunotherapy and chemotherapy (one-year DFS, P < 0.0001; two-year DFS, P = 0.002; three-year DFS, P = 0.02). An improved overall response rate (P = 0.009) was also observed in patients who received DC-CIK therapy. Furthermore, the analysis of T-lymphocyte subsets in peripheral blood indicated that the number of CD4⁺ T cells significantly increased in the DC-CIK plus chemotherapy group (P < 0.05). CONCLUSION The combination of DC-CIK immunotherapy and chemotherapy was superior in prolonging the survival time and enhancing immunological responses.